Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Punish the parent not the progeny.

Lucy J Elrick1, Heather G Jorgensen, Joanne C Mountford

  • 1Section of Experimental Haematology, Division of Cancer Sciences & Molecular Pathology, University of Glasgow, Level 3 Queen Elizabeth Bldg, Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, United Kingdom.

Blood
|November 6, 2004
PubMed
Summary

Targeted therapy for chronic myeloid leukemia (CML) leaves behind primitive, quiescent BCR-ABL+ cells. Eliminating these resistant cells is crucial for achieving molecular remission and potential cures in CML patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data Mining for Identification of Targets and Repurposed Drugs to Eliminate Persistent Chronic Myeloid Leukaemia Stem Cells: Targeting RAS/RAF Signalling.

Oncology research·2026
Same author

Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.

British journal of haematology·2026
Same author

Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies.

Stem cell reports·2026
Same author

A call to action for deciphering genetic variants in human pluripotent stem cells for cell therapy.

Cell stem cell·2025
Same author

The MYC-NFATC2 axis maintains the cell cycle and mitochondrial function in acute myeloid leukaemia cells.

Molecular oncology·2024
Same author

Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease.

Nature communications·2024

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myeloid leukemia (CML) is driven by BCR-ABL+ cells.
  • Targeted therapy like imatinib mesylate (IM) is effective but may not eradicate all CML cells.
  • A small population of quiescent, IM-insensitive CML cells persists after treatment.

Purpose of the Study:

  • To investigate the role of primitive, quiescent BCR-ABL+ cells in CML persistence.
  • To highlight the need for strategies targeting these resistant cells for disease eradication.

Main Methods:

  • Analysis of CML cell populations.
  • Assessment of sensitivity to imatinib mesylate (IM).

Main Results:

  • CML is sustained by primitive, quiescent BCR-ABL+ cells.

Related Experiment Videos

  • These cells are innately insensitive to IM despite higher BCR-ABL transcript levels.
  • Persistent CML cells explain molecular disease persistence after IM therapy.

    • Conclusions:

    • Complete disease eradication should be the goal in CML.
    • Allogeneic stem cell transplantation can achieve molecular clearance.
    • New approaches targeting primitive CML cells are essential for curative strategies.